INZY - Inozyme Pharma - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

238.6M

Cash

166.2M

Avg Qtr Burn

-19.36M

Short % of Float

11.24%

Insider Ownership

0.52%

Institutional Own.

92.73%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
INZ-701 (ENPP1-Fc) Pediatric Details Rare genetic disease, Genetic disorder, ENPP1 deficiency	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INZ-701 (ENPP1-Fc) Details ENPP1 deficiency, Genetic disorder, Rare genetic disease, ABCC6 Deficiency	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INZ-701 (ENPP1-Fc) Details End-stage renal disease	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INZ-701 (ENPP1-Fc) Details Rare genetic disease, Genetic disorder, ENPP1 deficiency	Phase 1 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.